Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: A GUSTO IV substudy

American Heart Journal

Volumn 147, Issue 2, 2004, Pages 267-274

  James, Stefan K ^a   Siegbahn, Agneta ^a   Armstrong, Paul ^b   Barnathan, Elliott ^c   Califf, Robert ^d   Simoons, Maarten L ^e   Wallentin, Lars ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CENTOCOR INC   (United States)

^d DUKE UNIVERSITY   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; DALTEPARIN; FIBRIN; FIBRINOGEN; INTERLEUKIN 6; PLACEBO; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; THROMBOCYTE;

EID: 0842304379     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.09.014     Document Type: Article

References (31)

1. Fuster V, Bodimon L, Cohen M, et al. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77:1213-20.
2. Lindohl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139-47.
3. Lindmork E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of on early invasive or noninvasive strategy. JAMA 2001;286:2107-13.
4. Toss H, Lindahl B, Siegbahn A, et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997;96:4204-10.
5. Oldgren J, Linder R, Grip L, et al. Coagulation activity and clinical outcome in unstable coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:1059-64.
6. Ardissino D, Merlini PA, Gamba G, et al. Thrombin activity and early outcome in unstable angina pectoris. Circulation 1996;93:1634-9.
7. Kruskal JB, Commerford PJ, Franks JJ, et al. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987;317:1361-5.
8. EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
9. CAPTURE investigators. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997;349:1429-35.
10. PURSUIT investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
11. Boersma E, Horrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
12. Lincoff AM, Kereiakes DJ, Moscelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-7.
13. Tam SH, Sossoli PM, Jordan RE, et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998;98:1085-91.
14. Moliterno DJ, Coliff RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial): Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559-62.
15. Ammor T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614-7.
16. GUSTO-IV-ACS investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on autome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial. Lancet 2001;357:1915-24.
17. James S, Armstrong P, Califf R, et al. Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. Eur Heart J 2002;23:1538-45.
18. Ernofsson M, Strekerud F, Toss H, et al. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998;79:491-4.
19. Koestenberger M, Gollistl S, Cvirn G, et al. Effects of the glycoprotein IIb/IIIa receptor antagonist c7E3 Fab and anticoagulants on platelet aggregation and thrombin potential under high coagulant challenge in vitro. Blood Coagul Fibrinolysis 2000;11:425-32.
20. Ottani F, Galvani M. Prognostic role of hemostatic markers in acute coronary syndromes patients. Clin Chim Acta 2001;311:33-9.
21. al-Nozha M, Gader AM, al-Momen AK, et al. Haemostatic variables in patients with unstable angina. Int J Cardiol 1994;43:269-77.
22. Fuster V, Chesebro JH. Mechanisms of unstable angina. N Engl J Med 1986;315:1023-5.
23. Hoffmeister HM, Heller W, Seipel L. Activation markers of coagulation and fibrinolysis: alterations and predictive value in acute coronary syndromes. Thromb Haemost 1999;82(Suppl):76-9.
24. James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003;41:916-24.
25. Bonz AW. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J 2003;145:693-9.
26. Ottervanger JP, Armstrong P, Barnathan ES, et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV-Acute Coronary Syndrome) trial. Circulation 2003;107:437-42.
27. Nannizzi-Alaimo L, Alves VL, Phillips DR, et al. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003;107:1123-8.
28. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002;71:176-85.
29. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000;20:2322-8.
30. Merlini PA, Repetto A, Lombardi A, et al. Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian hematologic substudy. Circulation 2002;105:928-32.
31. Goodman SG, Fitchett D, Armstrong PW. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-44.